Janux Therapeutics (NASDAQ:JANX) Raised to “Hold” at Wall Street Zen

Janux Therapeutics (NASDAQ:JANX) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Sunday.

A number of other equities research analysts have also issued reports on the company. Piper Sandler decreased their price target on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating for the company in a research note on Friday, January 16th. Clear Str cut Janux Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 20th. Cantor Fitzgerald dropped their target price on Janux Therapeutics from $150.00 to $100.00 and set an “overweight” rating on the stock in a research note on Friday, February 27th. Guggenheim cut their price objective on Janux Therapeutics from $72.00 to $68.00 and set a “buy” rating on the stock in a report on Friday, February 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Janux Therapeutics in a research note on Thursday, January 22nd. Eleven investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $56.91.

Janux Therapeutics Price Performance

Shares of JANX opened at $14.84 on Friday. The firm has a market cap of $902.72 million, a P/E ratio of -8.11 and a beta of 2.82. The company has a 50 day simple moving average of $13.70 and a two-hundred day simple moving average of $18.95. Janux Therapeutics has a 1 year low of $12.12 and a 1 year high of $35.34.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Thursday, February 26th. The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.14. The firm had revenue of $7.88 million for the quarter, compared to the consensus estimate of $0.08 million. On average, sell-side analysts anticipate that Janux Therapeutics will post -1.38 earnings per share for the current year.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently added to or reduced their stakes in JANX. California State Teachers Retirement System increased its holdings in shares of Janux Therapeutics by 1.1% in the second quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock valued at $858,000 after purchasing an additional 404 shares during the period. Nuveen LLC boosted its holdings in Janux Therapeutics by 0.8% during the fourth quarter. Nuveen LLC now owns 96,416 shares of the company’s stock worth $1,331,000 after buying an additional 787 shares in the last quarter. Congress Asset Management Co. grew its holdings in shares of Janux Therapeutics by 2.8% in the 4th quarter. Congress Asset Management Co. now owns 57,342 shares of the company’s stock worth $791,000 after acquiring an additional 1,569 shares during the period. ProShare Advisors LLC grew its holdings in Janux Therapeutics by 18.3% in the fourth quarter. ProShare Advisors LLC now owns 10,495 shares of the company’s stock valued at $145,000 after purchasing an additional 1,621 shares during the last quarter. Finally, Kennedy Capital Management LLC increased its holdings in Janux Therapeutics by 20.0% during the 3rd quarter. Kennedy Capital Management LLC now owns 11,413 shares of the company’s stock valued at $279,000 after acquiring an additional 1,905 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.